Medical Supply Chain Resiliency Act
HR 4307, the Medical Supply Chain Resiliency Act, establishes a framework for the U.S. to negotiate agreements with trusted foreign partners to secure reliable supplies of critical medical goods like drugs and devices. It directs the President to create "trusted trade partner agreements" with countries that maintain open trade during health emergencies, protect intellectual property, and reduce unnecessary trade barriers. These agreements would eliminate duties or restrictions on medical goods, diversify supplier networks, and harmonize regulatory standards to prevent shortages like those seen during the pandemic. The bill directly affects U.S. manufacturers, healthcare providers, and importers by aiming to reduce over-reliance on a few nations for essential medical products.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jun 2023
Committee Review
Floor Vote
President
Introduced Jun 22, 2023
Last action Dec 17, 2024
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Dec 17, 2024
Committee
Referred to the Subcommittee on Trade.
lower
Jun 22, 2023
Committee
Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jun 22, 2023
Introduced
Introduced in House
lower
1 primary · 7 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 4307
Scope: US
Hi! I can help you understand HR 4307. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline